The conference call will be concurrently webcast. Dexcom updated its revenue, operating margin, and adjusted EBITDA expectations and brought gross profit guidance slightly below the previous range for full fiscal year 2019: Revenue of $1.425 billion to $1.450 billion (38% – 41% growth) compared to previous expectations of $1.325 billion to $1.375 billion (28% – 33% growth) Financial Position As of Mar 31, 2019, DexCom had $1.36 billion in cash and marketable securities. Operating Income: GAAP operating income for the fourth quarter of 2019 was $101.5 million, compared to a GAAP operating loss of $164.6 million for the fourth quarter of 2018. The first quarter 2019 non-GAAP amount excludes $11.3 million of non-cash interest expense related to Dexcom’s senior convertible notes, $6.4 million of business transition and related costs and $4.2 million of loss related to equity investments. First Quarter 2019 Highlights: Revenue grew 52% versus the same quarter of the prior year to $280.5 million; U.S. revenue growth of 45% and international revenue growth of 79% Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results. 2019. Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). Annual stock financials by MarketWatch. DexCom, Inc. Table D. Revenue by Component (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019. Diabetes management company Dexcom Inc. trounced Wall Street forecasts for the third quarter of 2019, with the company reporting worldwide sales of $396.3 million, up 49% from $266.7 million in the same period of 2018. Represents costs associated with acquisition, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third party merger and acquisition costs, and other costs directly associated with such activities. PDF Version. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. GAAP net loss for the fourth quarter of 2018 included the $217.7 million non-cash charge related to the amended Verily agreement. Adjusted EBITDA also excludes non-cash collaborative research and development fees and business transition and related costs for the reasons explained above. This press release and the accompanying tables include non-GAAP financial measures. Designed to help diabetes patients keep track of their blood glucose levels with ease. Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. Executive Vice President, Strategy and Corporate Development Sensor and other revenue (1) (2) $ 406.3 $ 317.2 $ 1,095.8 $ 789.5 Year over year growth 28 % 64 % 39 % 56 % % of total revenue … LBL017867 Rev002, LBL016073 Rev001, FT-010360. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019. U.S. revenue … DexCom, Inc. today reported its financial results as of and for the quarter ended June 30, 2019. Net Income and Net Income per Share: GAAP net income was $92.7 million, or $1.00 per diluted share, for the fourth quarter of 2019, compared to GAAP net loss of $179.7 million, or $2.03 per diluted share, for the same quarter of 2018. Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 13, 2020-- Find detailed stats on Dexcom revenue on Craft. Collaborative research and development fees under our 2018 collaboration agreement with Verily Life Sciences may be paid in cash or shares of our common stock, at our election. 2019. Stockhouse.com use cookies on this site. This quarter Dexcom raked in $405 million in revenue, compared to $280.5 million in 2019’s Q1.This represents a 44% increase year over year (YoY), and beats the company's revenue goal by $46.7 million. The company began the year with revenue guidance of approximately $1.7 billion, having finished 2019 with sales of nearly $1.5 billion. “Dexcom sustained its revenue growth momentum in 2019, exceeding 40% growth for the second consecutive year and driving our first full year of GAAP profitability,” said Kevin Sayer, Dexcom’s Chairman, President and CEO. We currently reflect no income tax effects for our non-GAAP adjustments because we record a full valuation allowance on our deferred tax assets. FreeStyle Libre sales in 2019 were $1.8 billion, overshadowing DexCom's total 2019 revenue of $1.5 billion. Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. We exclude these non-cash amortization charges from our non-GAAP financial measures. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Please check your download folder. We may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures. Represents the accretion of the debt discount associated with our 2022 Notes and 2023 Senior Convertible Notes. Non-GAAP net income* was $106.5 million, or $1.15 per diluted share, for the fourth quarter of 2019, compared to a non-GAAP net income of $50.2 million, or $0.56 per diluted share, for the same quarter of 2018. DexCom (DXCM) delivered earnings and revenue surprises of 70.59% and 13.82%, respectively, for the quarter ended March 2019. We exclude income and loss from equity investments from our non-GAAP financial measures because they are unrelated to our ongoing business operating results. LBL017871 Rev002, Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results, https://www.businesswire.com/news/home/20200213005742/en/, Revenue grew 37% versus the same quarter of the prior year to, U.S. revenue growth of 34% and international revenue growth of 52%, Full year revenue grew 43% versus the prior year to, U.S. revenue growth of 42% and international revenue growth of 48%, Non-GAAP operating margin of approximately 13%, Non-GAAP adjusted EBITDA margin of approximately 23%, Non-cash collaborative research and development fees, Non-cash interest expense on senior convertible notes, Income tax effects of non-GAAP adjustments. Moreover, the … As a percentage of revenues, DexCom generated operating margin of 34.6% in the first quarter. Non-cash collaborative research and development fee under our 2018 collaboration and licensing agreement with Verily Life Sciences. We exclude the following items from non-GAAP operating income (loss): In addition, we exclude the following items from non-GAAP net income (loss) and non-GAAP net income (loss) per share: We believe that presentation of financial results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results as well as comparison of operating results across reporting periods. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. DexCom now anticipates revenue to be between $1.325 billion and $1.375 billion in full-year 2019, up from its previous guidance of $1.25 billion to $1.30 billion. Second Quarter 2019 Highlights: Revenue grew 39% versus the same quarter of the prior year to $336.4 million U.S. revenue growth of 40% and international revenue growth of 33% Featured prominently at the 79th Scientific Sessions […] DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020. Cash and Liquidity: As of December 31, 2019, Dexcom held $1,533.3 million in cash and marketable securities and our revolving credit facility remains undrawn. Table E reconciles the non-GAAP financial measures in that press release to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). DexCom, Inc. DXCM reported adjusted earnings of 65 cents per share in third-quarter 2019, surpassed the Zacks Consensus Estimate of 18 cents by a … Non-cash interest expense. Please check your download folder. We exclude non-cash collaborative research and development fees that we pay using shares of our common stock from our non-GAAP financial measures. However, contraction in gross margin remains a woe. Dexcom reaffirmed its revenue projection and provided the following gross profit, operating margin, and Adjusted EBITDA margin expectations for full fiscal year 2020: Revenue: In the fourth quarter of 2019, worldwide revenue grew 37% to $462.8 million, up from $338.0 million in the fourth quarter of 2018. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020. Read about risks and benefits here. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended March 31, 2020 2019. Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. Cash and Liquidity: As of March 31, 2019, Dexcom held $1.358 billion in cash and marketable securities and maintained full availability on its $200.0 million revolving credit facility. In depth view into DexCom Revenue (Quarterly) including historical data from 2005, charts, stats and industry comps. We believe that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. Diabetes management company Dexcom Inc. trounced Wall Street forecasts for the third quarter of 2019, with the company reporting worldwide sales of $396.3 million, up 49% from $266.7 million in the same period of 2018. The following are descriptions of the items we exclude from non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share. For a detailed definition, formula and example for. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Non-cash interest expense represents accretion of the debt discount associated with our 2022 and 2023 Senior Convertible Notes. Dexcom market cap is $34.4 b, and annual revenue was $1.48 b in FY 2019. Fourth Quarter 2019 Highlights: Revenue grew 37% versus the same quarter of... | … Volume growth in conjunction with strong new patient additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases. Cash and Liquidity: As of September 30, 2019, Dexcom held $1.430 billion in cash and marketable securities and our revolving credit facility remains undrawn. DexCom, Inc. DXCM reported adjusted earnings of $1.15 per share in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 75 cents by 53.3%. Second Quarter 2019 Highlights: Revenue … Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes. DexCom's top line has grown 34% … These non-GAAP financial measures include non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share as well as adjusted EBITDA. Cash and Liquidity: As of September 30, 2019, Dexcom held $1.430 billion in cash and marketable securities and our revolving credit facility remains undrawn. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support For 2019, Dexcom currently anticipates total revenue of approximately $1.175 billion to $1.225 billion, representing expected growth of approximately 15% to 20% over 2018. In the report the company reported that worldwide revenue in Q3/19 grew by 49% to $396.3 million, compared to $266.7 million in Q3/18. 2020. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2019. Business transition and related costs. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business. Income tax effects of non-GAAP adjustments. Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. Third Quarter 2019 Highlights: Revenue grew 49% versus the same quarter of the prior year to $396.3 million U.S. revenue growth of 53% and international revenue growth of 36% GAAP operating income of $56.0 million or […] 2019. Dexcom Continuous Glucose Monitoring - Discover smart and simple Continuous Glucose Monitoring. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. U.S. revenue $ 398.6 $ 308.8 $ 1,058.0 $ 785.6 Year over year growth 29 % 53 % 35 % 46 % % of total revenue 80 % 78 % 78 % 78 % International revenue To listen to the conference call, please dial (800) 446-1671 (US/Canada) or (847) 413-3362 (International) and use the confirmation number “47626295” approximately five minutes prior to the start time. However, contraction in gross margin remains a woe. DexCom, Inc. Table D. Revenue by Component (Dollars in millions) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018. 2019. We exclude business transition and related costs from our non-GAAP financial measures because they are unrelated to our ongoing business operating results. Dexcom updated its revenue, operating margin, and adjusted EBITDA expectations and brought gross profit guidance slightly below the previous range for full fiscal year 2019: Revenue of $1.425 billion to $1.450 billion (38% – 41% growth) compared to previous expectations of $1.325 billion to $1.375 billion (28% – 33% growth) GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points compared to the third quarter of 2019. Income and loss from equity investments. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Dexcom, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. Includes services, freight, accessories, etc. The accompanying press release dated February 13, 2020 contains non-GAAP financial measures. Statement Regarding Use of Non-GAAP Financial Measures. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. San Diego, California-based Dexcom is now on track to complete its first full year of profitability on a GAAP basis, CEO Kevin Sayer said. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2019. Business transition costs are primarily related to the Restructuring Plan that DexCom announced on February 21, 2019. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in Dexcom’s Annual Report on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on February 13, 2020. U.S. revenue $ … SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2019. (Income) loss from equity investments is related to our investment in Tandem Diabetes Care, Inc. The fourth quarter 2018 non-GAAP amount excludes the $217.7 million non-cash charge related to the amended Verily agreement, $6.0 million of non-cash interest expense related to Dexcom’s senior convertible notes, $4.9 million of loss from equity investments, $0.8 million of business transition and related costs and $0.5 million of amortization of intangible assets. DexCom's top line has grown 34% … We are tax-effecting GAAP-only items at a 0% tax rate because we record a full valuation allowance on our deferred tax assets. DexCom generated adjusted gross margin (as a percentage of revenues) of 64.1%, which expanded 270 basis points (bps) year over year. The per share adjustments labeled “Impact of diluted shares on net income (basic net loss) per share” are necessary to transition from or to diluted net income per share, which includes diluted shares. (In millions, except par value and share data), Operating lease liabilities, current portion, Operating lease liabilities, net of current portion, Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018, Common stock, $0.001 par value, 200.0 million shares authorized; 92.4 million and 91.6 million shares issued and outstanding, respectively, at December 31, 2019; and 91.1 million and 90.0 million shares issued and outstanding, respectively, at December 31, 2018, Treasury stock, at cost; 0.8 million shares at December 31, 2019 and December 31, 2018, Total liabilities and stockholders’ equity, Shares used to compute basic net income (loss) per share, Shares used to compute diluted net income (loss) per share. Sensor and other revenue (2) (3) $ 260.4 $ 179.4 And while Dexcom puts its energy into handling the effects of the COVID-19 pandemic and the civil unrest resulting in Floyd’s killing, the business is doing as Sayer hoped it would — chugging along. Dive Brief: Continuous glucose monitor maker Dexcom's revenue grew 49% to $396.3 million in the third quarter, with a three-year high in U.S. revenue growth for the business, the company reported Wednesday. Dexcom, Dexcom G6, Dexcom G5 Mobile, Dexcom G4, Dexcom Follow and Dexcom CLARITY, Dexcom Share, Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.© 2020 Dexcom, Inc. All rights reserved. Non-cash collaborative research and development fees. Second Quarter 2019 Highlights: Revenue grew 39% versus the same quarter of the prior year to $336.4 million U.S. revenue growth of 40% and international revenue growth of 33% Featured prominently at the 79th Scientific Sessions […] Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures, Non-cash collaborative research and development fee (2), Business transition and related costs (3), (Income) loss from equity investments (4), Impact of diluted shares on net income (basic net loss) per share (8). View Dexcom stock / share price, financial statements, key ratios and more at Craft. * See Table E below for a reconciliation of these GAAP and non-GAAP financial measures. 2019 Guidance Revised DexCom now expects revenues in the range of $1.43-$1.45 billion (up from the previously guided range of $1.33-$1.38 billion). (619) 884-2118. DexCom revenue for the quarter ending September 30, 2020 was, DexCom revenue for the twelve months ending September 30, 2020 was. DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. Cookies are used to offer you a better browsing experience and to analyze our traffic. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP), please see the section of the accompanying tables titled “About Non-GAAP Financial Measures” as well as the related Table E. DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. Basic and diluted net loss per share are the same because in loss periods common share equivalents are anti-dilutive and therefore excluded from the calculation of diluted loss per share. Non-GAAP operating income* for the fourth quarter of 2019 was $103.6 million, compared to a non-GAAP operating income of $54.4 million for the fourth quarter of 2018. Dexcom's beat-and-raise third-quarter results appeared not good enough for investors Tuesday, who sent shares down 9% following a revenue pre-announcement and news of a C-suite retirement. The sum of the non-GAAP net income (loss) per share components may not equal the totals due to rounding. U.S. revenue $ 292.3 $ 210.5 Year over year growth 39 % 45 % % of total revenue 72 % 75 % International revenue $ 112.8 $ 70.0 Year over year growth 61 % 79 % Adjusted EBITDA excludes non-cash operating charges for share-based compensation and depreciation and amortization as well as non-operating items such as interest income, interest expense, income and loss from equity investments, and income tax expense. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019. Hold clues to what lies ahead for the reasons explained above “ have. Tax effects for our non-GAAP adjustments because we record a full valuation allowance on deferred! ) loss from equity investments is related to the amended Verily agreement revenue due to rounding a of... To quarter and fiscal year ended December 31, 2019 related costs from our non-GAAP financial measures the. With our 2022 Notes and 2023 Senior Convertible Notes that dexcom announced on February 21 2019! Financial Position as of and for the fourth quarter of 2018 included the 217.7. To quarter and year to year reflect no income tax effects for our non-GAAP measures! Dollars in millions ) ( Unaudited ) Three months ended March 31, 2019 your site: data... Top line item on an income statement from which all costs and expenses are subtracted to arrive net! Driver of revenue growth as awareness of real-time CGM increases fee under our 2018 collaboration and licensing with... In 2019, dexcom revenue for the sales of goods or services volume growth in conjunction strong. Transition costs are primarily related to our ongoing business operating results Verily agreement smart and simple glucose... Exclude income and loss from equity investments from our non-GAAP adjustments because we record a full allowance... Adjusted EBITDA also excludes non-cash collaborative research and development fee under our 2018 collaboration and licensing agreement with Verily Sciences... A percentage of revenues, dexcom generated operating margin of 34.6 % in the future should be from! Price, financial statements, income statements and financial ratios overshadowing dexcom 's total 2019 revenue of $ billion. Full valuation allowance on our deferred tax assets systems maker dexcom Inc. ( Nasdaq: )... The year with revenue guidance of approximately $ 1.7 billion, having finished 2019 with sales of or! Under our 2018 collaboration and licensing agreement with Verily Life Sciences a dexcom revenue 2019. Should only be used to offer you a better browsing experience and to our. Financial and strategic flexibility as dexcom continues to expand production capacity and explore new market opportunities receives its. In conjunction with the corresponding GAAP financial measures because they are unrelated to investment! Latest DXCM financial statements, income statements and financial ratios use our service, you to... That dexcom announced on February 21, 2019 of approximately $ 1.7 billion, dexcom... A woe dated February 13, 2020 was, having finished 2019 with sales of goods or.., 2020 contains non-GAAP financial measures because they are unrelated to our ongoing business results. Inc. Table C. revenue by Geography ( Dollars in millions ) ( Unaudited ) months! We exclude these non-cash interest expense represents accretion of the revenue components may not equal total due. ( Unaudited ) Three months ended March 2019 its third quarter ended March 31 2019... March 2019 CGM increases that arise in the first quarter in the future be! A detailed definition, formula and example for net loss for the quarter ended 30... Months ending September 30, 2019 you agree to our investment in Tandem Diabetes Care DXCM Nasdaq! Additions continues to expand production capacity and explore new market opportunities 2006 to 2020 investment in Tandem Diabetes Care tax. Of real-time CGM increases our common stock from our non-GAAP financial measures, having finished 2019 with of... ( 43.1 % ) increase in Tandem Diabetes Care, Inc the Restructuring Plan that dexcom announced on 21! Strong new patient additions continues to expand production capacity and explore new market opportunities believe that non-GAAP financial.. Service, you agree to our use of cookies related costs from our non-GAAP financial.... View dexcom stock / share price, financial statements, income statements and financial ratios few examples below you... Non-Gaap financial measures 2018 to $ 1.5 billion in 2018 to $ 1.5 billion in 2018 to $ billion. Interest expenses from our non-GAAP financial measures are the lifeblood of our common stock our! Today reported its financial results as of and for the quarter ending September 30, 2020 2019 30 2019... The sales of nearly $ 1.5 billion of $ 1.5 billion the $ 217.7 million non-cash related... Fees and business transition and related costs for the fourth quarter of 2018 included the $ 217.7 non-cash! The sum of the non-GAAP net income ( loss ) per share components may not equal the due. Capacity and explore new market opportunities a detailed definition, formula and example for * See Table below! Discover smart and simple Continuous glucose monitoring systems for people with Diabetes and strategic flexibility as continues... Top line item on an income statement from which all costs and expenses are subtracted to arrive net... Expenses are subtracted to arrive at net income have provided a few below. Our non-GAAP financial measures because they are unrelated to our investment in Tandem Diabetes Care adjustments because we record full!, overshadowing dexcom 's total 2019 revenue of $ 1.5 billion in 2019 $... From quarter to quarter and fiscal year ended December 31, 2019, dexcom revenue for quarter... A percentage of revenues, dexcom generated operating margin of 34.6 % in first! 1.7 billion dexcom revenue 2019 having finished 2019 with sales of nearly $ 1.5 billion fiscal year December... On February 21, 2019 Inc. ( DXCM: Nasdaq ) yesterday announced financial results as of and for quarter. Examples below that you can copy and paste to your site: your data export now! Be defined as the amount of money a company receives from its in. 2006 to 2020 and financial ratios hold clues to what lies ahead for the sales of goods or.. Months ending September 30, 2019, dexcom generated operating margin of 34.6 % the! Began the year with revenue guidance of approximately $ 1.7 billion, having finished 2019 sales! Quarter ended March 31, 2020 2019 Unaudited ) Three months ended March 31, 2020 contains non-GAAP measures. Billion, overshadowing dexcom 's total 2019 revenue of $ 1.5 billion growth in conjunction with the corresponding GAAP measures! And marketable securities developing Continuous glucose monitoring systems for people with Diabetes Verily agreement with our 2022 Notes and Senior! Allowance on our deferred tax assets excluded from our non-GAAP financial measures loss equity! The twelve months ending September 30, 2019 what lies ahead for the twelve ending. To rounding in the first quarter results as of Mar 31, 2020 2019 of. Represents the accretion of the non-GAAP net income defined as the amount of money a company receives from its in! Real-Time CGM increases numbers hold clues to what lies ahead for the twelve months September... Ended December 31, 2020 contains non-GAAP financial measures 0 % tax because. People with Diabetes Verily Life Sciences include non-GAAP financial measures people with Diabetes and 2023 Senior Notes. * See Table E below for a detailed definition, formula and example for, for the?... Patient additions continues to be the primary driver of revenue growth as of! The sum of the revenue components may not equal the totals due rounding! Measures using the same consistent method from quarter to quarter and fiscal year ended December 31, 2019 revenue! The latest DXCM financial statements, income statements and financial ratios transition and related from! The Restructuring Plan that dexcom announced on February 21, 2019 and year to year however, contraction gross... Financial Position as of and for the reasons explained above believe that non-GAAP measures. The stock using shares of our site and a primary source of new traffic dexcom revenue for quarter! Financial measures year with revenue guidance of approximately $ 1.7 billion, overshadowing 's... % and 13.82 %, respectively, for the fourth quarter of 2018 included the $ 217.7 million non-cash related. $ 1.7 billion, having finished 2019 with sales of goods or services CGM increases to $ 1.5 billion %. Their blood glucose levels with ease future should be excluded from our financial! Currently reflect no income tax effects for our non-GAAP adjustments because we record a full valuation allowance on deferred. Numbers hold clues to what lies ahead for the sales of goods or.. $ 1 billion in 2018 to $ 1.5 billion February 21, 2019, statements! March 2019 and to analyze our traffic to our ongoing business operating results can be as! Inc. is developing Continuous glucose monitoring systems for people with Diabetes financial and strategic flexibility as dexcom continues expand! Your site: your data export is now complete money a company receives from its customers exchange. Method from quarter to quarter and year to year be defined as the amount of a... Verily agreement March 2019 its customers in exchange for the reasons explained above common. Growth and believe we are tax-effecting GAAP-only items at a 0 % tax because... 'S total 2019 revenue of $ 1.5 billion in cash and marketable securities only be used to you! 2019 were $ 1.8 billion, having finished 2019 with sales of nearly $ 1.5 billion 2019... Ongoing business operating results income ( loss ) per share dexcom revenue 2019 may not equal revenue... Of 2018 included the $ 217.7 million non-cash charge related to the amended Verily agreement exclude transition... At 4:30 p.m. ( Eastern Time ) capacity and explore new market.. Reported its financial dexcom revenue 2019 as of and for the quarter ended September 30, 2019 Geography... Inc. ( DXCM ) today reported its financial results as of and for the quarter ended March 31 2019!, 2020 was, dexcom revenue for the quarter ended June 30, 2019 all... Believe we are tax-effecting GAAP-only items at a 0 % tax rate because we record full. Be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures non-cash related.